BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations
SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate…
Filmio Studios Unveils New Fan-Commitment Data Layer as Superfan Beta Reveals Early Greenlighting Signals
Best SEO Software for Agencies: Tools Moving Services Are Using
VyOS Networks Announces VyOS 1.4.4 LTS Release, Reinforcing the Universal Networking Platform for Hybrid Cloud and Edge